Why the study?
Obesity is associated with increased cardiovascular morbidity, and adult patients with growth hormone deficiency exhibit morpho-functional cardiological alterations.
Is growth hormone deficiency associated with worse cardiac morphology, function, and metabolic phenotype in overweight and obese patients?
Is growth hormone deficiency associated with worse cardiac morphology, function, and metabolic phenotype in overweight and obese patients?
Growth hormone deficiency in overweight and obese patients is associated with worse metabolic health, visceral adiposity, and adverse cardiac morpho-functional alterations.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open whether GH secretory capacity is a treatable driver of cardiometabolic risk in obesity.
Obesity is associated with increased cardiovascular morbidity. Adult patients with growth hormone deficiency (GHD) show morpho-functional cardiological alterations. A total of 353 overweight/obese patients are enrolled in the period between 2009 and 2019 to assess the relationships between GH secretory capacity and the metabolic phenotype, cardiovascular risk factors, body composition and cardiac echocardiographic parameters. All patients underwent GHRH + arginine test to evaluate GH secretory capacity, DEXA for body composition assessment and transthoracic echocardiography. Blood samples are also collected for the evaluation of metabolic parameters. In total, 144 patients had GH deficiency and 209 patients had normal GH secretion. In comparing the two groups, we found significant differences in body fat distribution with predominantly visceral adipose tissue accumulation in GHD patients. Metabolic syndrome is more prevalent in the GHD group. In particular, fasting glycemia, triglycerides and systolic and diastolic blood pressure are found to be linearly correlated with GH secretory capacity. Epicardial fat thickness, E/A ratio and indexed ventricular mass are worse in the GHD group. In the population studied, metabolic phenotype, body composition, cardiovascular risk factors and cardiac morphology are found to be related to the GH secretory capacity. GH secretion in the obese patient seems to be an important determinant of metabolic health.
No takes yet. Share an insight, caveat, or question.
Gangitano et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: